Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

OxyContin Neo - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/OxyContin Neo

Approved

STANDARD

OxyContin Neo

Purdue Pharmaceuticals L.P.🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: d98cfe3cbb0c8fb1
Company: Purdue Pharmaceuticals L.P.
Type: Standard

Approval Details

Approval Id: d98cfe3cbb0c8fb1
Drug Approval Philippines Name: OxyContin Neo
Product Name: OxyContin Neo
Registration Number: DR-XY45710
Brand Name: OxyContin Neo
Generic Name: Oxycodone hydrochloride
Dosage Form: Controlled-Release Tablet
Dosage Strength: 80mg
Manufacturer: Purdue Pharmaceuticals L.P.
Importer: Mundipharma Distribution GmBH (Philippine Branch)
Company Detail Path: /organization/purdue-pharmaceuticals-l-p
Issuance Date: 23 September 2021
Expiry Date: 15 December 2026
Pharmacologic Category: Opioid Analgesic
Classification: Prescription Drug (Rx)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

d98cfe3cbb0c8fb1

Type

Standard

Back to Philippines FDA Approvals